Director — Carol L. Brosgart: The filing discloses the appointment of a new director, which is a routine board composition change and not an executive departure.

Entry into Material Definitive Agreement. On July 31, 2026, Cocrystal Pharma, Inc. (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with OPKO Health, Inc., an accredited investor (the “Purchaser”), pursuant to which the Company sold and issued to the Purchaser a total of 5,474,053 shares of the Company’s common stock at a purchase price of $0.9134 per share, the Nasdaq Consolidated Bid Price on the trading day of closing, resulting in gross proceeds to the C…

The sale of shares was exempt from registration based upon Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder. The Purchaser is an accredited investor and acquired the shares for investment.

Regulation FD Disclosure. On August 3, 2026, the Company issued a press release announcing the private placement described above in

Chief Executive Officer — James Sapirstein: James Sapirstein was appointed as the new CEO of Cocrystal Pharma, Inc.

Results of Operations and Financial Condition. On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal year ended December 31, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liabili…

Director — Dr. Anthony Japour: Dr. Anthony Japour, a member of the Company’s board of directors, passed away.

The filing describes the grant of stock options and a cash award, which are routine compensatory arrangements.

Results of Operations and Financial Condition On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liab…

The sale of units was exempt from registration based upon Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder. Each Purchaser is an accredited investor and acquired the units for investment.

Entry into Material Definitive Agreement. On October 28, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with four accredited investors (the “Purchasers”) under which the Purchasers purchased a total of 739,426 units of the Company’s securities. The units were priced at-the-market under the rules of the Nasdaq Stock Market at a purchase price of $1.39 per unit. Each unit consisted of one share of common s…

Regulation FD Disclosure. On October 30, 2025, the Company issued a press release announcing the private placement described above in

Entry into a Material Definitive Agreement. Registered Direct Offering On September 12, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with certain accredited investors (each, an “Investor” and collectively the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors (i) in a registered direct offering, an aggregate of 2,764,710 shares (the “Shares”) of the Company’s common stock, par…

Unregistered Sale of Equity Securities. The information set forth in

Regulation FD Disclosure. On September 12, 2025, Cocrystal Pharma, Inc. (“the Company”) issued a press release announcing the pricing of a registered direct offering of common stock and a concurrent private placement of warrants. A copy of the press release is furnished as Exhibit 99.1. The information contained in the press releases attached as Exhibit 99.1, respectively, to this Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or other…

Results of Operations and Financial Condition On August 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…

Results of Operations and Financial Condition On May 15, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchan…

The filing describes the adoption of a new equity incentive plan, which is not directly related to management changes.

Results of Operations and Financial Condition On March 31, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…

Results of Operations and Financial Condition On November 13, 2024, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securiti…

The company approved salary increases, bonuses, and RSU grants for its executive officers and non-employee directors.

Results of Operations and Financial Condition On August 14, 2024, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…

Results of Operations and Financial Condition On May 13, 2024, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2024, and providing updates on its antiviral drug development programs. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to…

Results of Operations and Financial Condition On March 28, 2024, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exch…

Termination of Material Definitive Agreement. On February 28, 2024, Cocrystal Pharma, Inc. (the “Company”) provided notice to Kansas State University Research Foundation of the Company’s election to terminate the License Agreements (the “Agreements”) dated February 12, 2020 and April 19, 2020. The terminations, which were made due to the Company’s determination that further development efforts under the Agreements would be futile, are effective on March 29, 2024. The material terms of the Agr…